Mark J. Ernsting

3.0k total citations · 1 hit paper
36 papers, 2.4k citations indexed

About

Mark J. Ernsting is a scholar working on Biomaterials, Biomedical Engineering and Oncology. According to data from OpenAlex, Mark J. Ernsting has authored 36 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Biomaterials, 13 papers in Biomedical Engineering and 11 papers in Oncology. Recurrent topics in Mark J. Ernsting's work include Nanoparticle-Based Drug Delivery (18 papers), Nanoplatforms for cancer theranostics (10 papers) and Cancer Treatment and Pharmacology (4 papers). Mark J. Ernsting is often cited by papers focused on Nanoparticle-Based Drug Delivery (18 papers), Nanoplatforms for cancer theranostics (10 papers) and Cancer Treatment and Pharmacology (4 papers). Mark J. Ernsting collaborates with scholars based in Canada, United States and Netherlands. Mark J. Ernsting's co-authors include Shyh‐Dar Li, Mami Murakami, Aniruddha Roy, Tatsuaki Tagami, Elijus Undzys, Jonathan P. May, Warren D. Foltz, Wei-Lun Tang, Bryan Hoang and Carol Lee and has published in prestigious journals such as Biomaterials, Cancer Research and Journal of Controlled Release.

In The Last Decade

Mark J. Ernsting

36 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles

2013 811 citations Mark J. Ernsting, Mami Murakami et al. Journal of Controlled Release profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark J. Ernsting Canada	20	1.5k	1.2k	756	318	233	36	2.4k
Tania Betancourt United States	21	1.3k 0.9×	1.3k 1.0×	910 1.2×	174 0.5×	441 1.9×	43	2.7k
James D. Byrne United States	19	1.4k 1.0×	1.2k 1.0×	951 1.3×	182 0.6×	423 1.8×	45	2.9k
Efstathios Karathanasis United States	27	1.3k 0.9×	1.3k 1.1×	721 1.0×	236 0.7×	411 1.8×	49	2.5k
Jianhua Zhu China	23	1.1k 0.7×	829 0.7×	904 1.2×	169 0.5×	398 1.7×	43	2.2k
Michael Chorny United States	25	1.2k 0.8×	891 0.7×	779 1.0×	146 0.5×	320 1.4×	64	2.6k
Peisheng Xu United States	32	1.3k 0.9×	1.2k 0.9×	1.3k 1.7×	235 0.7×	440 1.9×	63	3.3k
Ayuob Aghanejad Iran	36	934 0.6×	1.2k 1.0×	866 1.1×	344 1.1×	317 1.4×	81	2.7k
Shiqun Shao China	20	1.0k 0.7×	1.3k 1.0×	852 1.1×	209 0.7×	321 1.4×	63	2.2k
Liangran Guo China	21	998 0.7×	1.2k 0.9×	982 1.3×	160 0.5×	619 2.7×	27	2.5k
Einar Sulheim Norway	17	834 0.6×	1.2k 1.0×	603 0.8×	189 0.6×	467 2.0×	26	2.0k

Countries citing papers authored by Mark J. Ernsting

Since Specialization

Citations

This map shows the geographic impact of Mark J. Ernsting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ernsting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ernsting more than expected).

Fields of papers citing papers by Mark J. Ernsting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Ernsting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ernsting. The network helps show where Mark J. Ernsting may publish in the future.

Co-authorship network of co-authors of Mark J. Ernsting

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Ernsting. A scholar is included among the top collaborators of Mark J. Ernsting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Ernsting. Mark J. Ernsting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoang, Bryan, et al.. (2017). Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer Letters. 410. 169–179. 37 indexed citations

Ernsting, Mark J., Bryan Hoang, Ines Lohse, et al.. (2015). Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. Journal of Controlled Release. 206. 122–130. 114 indexed citations

Roy, Aniruddha, Mark J. Ernsting, Elijus Undzys, & Shyh‐Dar Li. (2015). A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors. Biomaterials. 52. 335–346. 70 indexed citations

Hoang, Bryan, Mark J. Ernsting, Aniruddha Roy, et al.. (2015). Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials. 59. 66–76. 66 indexed citations

Hoang, Bryan, Mark J. Ernsting, Mami Murakami, Elijus Undzys, & Shyh‐Dar Li. (2014). Docetaxel–carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. International Journal of Pharmaceutics. 471(1-2). 224–233. 37 indexed citations

Murakami, Mami, et al.. (2013). Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin–Expressing Stromal Cells Suppress Breast Cancer Metastasis. Cancer Research. 73(15). 4862–4871. 110 indexed citations

Ernsting, Mark J., et al.. (2012). A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. Journal of Controlled Release. 162(3). 575–581. 83 indexed citations

Ernsting, Mark J., Warren D. Foltz, Elijus Undzys, Tatsuaki Tagami, & Shyh‐Dar Li. (2012). Tumor-targeted drug delivery using MR-contrasted docetaxel – Carboxymethylcellulose nanoparticles. Biomaterials. 33(15). 3931–3941. 46 indexed citations

Ernsting, Mark J., et al.. (2011). Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials. 33(5). 1445–1454. 94 indexed citations

10.

Tagami, Tatsuaki, Mark J. Ernsting, & Shyh‐Dar Li. (2011). Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. Journal of Controlled Release. 154(3). 290–297. 125 indexed citations

11.

Tagami, Tatsuaki, Mark J. Ernsting, & Shyh‐Dar Li. (2011). Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. Journal of Controlled Release. 152(2). 303–309. 131 indexed citations

12.

Tagami, Tatsuaki, Warren D. Foltz, Mark J. Ernsting, et al.. (2011). MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 32(27). 6570–6578. 165 indexed citations

13.

Ernsting, Mark J., et al.. (2011). Ultrasound drug targeting to tumors with thermosensitive liposomes. ePrints Soton (University of Southampton). 1–4. 11 indexed citations

14.

Blit, Patrick H., Yi Shen, Mark J. Ernsting, Kimberly A. Woodhouse, & J. Paul Santerre. (2010). Bioactivation of porous polyurethane scaffolds using fluorinated RGD surface modifiers. Journal of Biomedical Materials Research Part A. 94A(4). 1226–1235. 10 indexed citations

15.

Ernsting, Mark J., et al.. (2007). The Acute Effects of Twenty-Four Hours of Sleep Loss on the Performance of National-Caliber Male Collegiate Weightlifters. The Journal of Strength and Conditioning Research. 21(4). 1146–1146. 80 indexed citations

16.

Ernsting, Mark J., Rosalind S. Labow, & J. Paul Santerre. (2007). Human monocyte adhesion onto RGD and PHSRN peptides delivered to the surface of a polycarbonate polyurethane using bioactive fluorinated surface modifiers. Journal of Biomedical Materials Research Part A. 83A(3). 759–769. 14 indexed citations

17.

Ernsting, Mark J., et al.. (2005). Generation of cell adhesive substrates using peptide fluoralkyl surface modifiers. Biomaterials. 26(33). 6536–6546. 30 indexed citations

18.

Ernsting, Mark J., Rosalind S. Labow, & J. Paul Santerre. (2003). Surface modification of a polycarbonate-urethane using a vitamin-E-derivatized fluoroalkyl surface modifier. Journal of Biomaterials Science Polymer Edition. 14(12). 1411–1426. 10 indexed citations

19.

Ernsting, Mark J., et al.. (1992). Spinaler extraduraler Abszeß bei M. Crohn. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 157(9). 286–287. 2 indexed citations

20.

Ernsting, Mark J., et al.. (1953). [Studies of spasmolytics. I. Mandelic acid esters].. PubMed. 3(10). 503–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact